About us
All the communication power of the leading platform for generating and distributing informative content in Spanish for institutions and companies. EFEComunica is a Spanish international news agency service that provides advice on communications, generates and promotes content and organizes events for institutions and companies.
EFECOMUNICA REACHES EVERYONE
EFEComunica offers extensive impact through more than 1,800 Spanish and international media subscribers to the services of the world’s leading news agency in Spanish, Agencia EFE.
A GLOBAL TEAM
EFEComunica has an extensive network of multidisciplinary professionals in 120 countries, whose specialization contributes to all production stages of EFEComunica products and services, focused on Spanish-speaking markets and helping to improve presence and notoriety in social networks.
SPECIALIZATION AND AUTHENTICITY
EFEComunica’s extensive experience in communication strategies and 360º solutions, as well as its knowledge in the areas of health, the environment, food and agriculture, feminism, tourism, and technology, makes it a great ally to shape your project.
EFEComunica defines strategies to help you tell your story.
Services and products

Content generation
Quality content adapted to any format or media type.

Impact
Promotion and visibility for your content. Targeting the main Spanish-speaking media in any country in the world.

Events
Matters of special interest promoted on the public agenda. Strategic information generated for each market.

Virtual press room
A meeting point is created between your company and the media.

Communications consultancy
EFEComunica provides advice on establishing a communication strategy, positioning your brand and strengthening your notoriety.
Last content

Meltwater named a Leader in the 2026 Gartner® Magic Quadrant™ for PR and Media Monitoring Tools
Meltwater named a Leader in the 2026 Gartner® Magic Quadrant™ for PR and Media Monitoring Tools Meltwater placed highest in Ability to Execute and furthest

Asyad Group to host Muscat Maritime Resilience Forum to strengthen global trade networks
Statement issued by the company (Announcement) In partnership with the Foreign Ministry, the Ministry of Transport, Communications and Information Technology, and Oman Investment Authority, Asyad

Junshi Biosciences announces completion of first patient dosing in the phase 3 clinical trial of JS203 in combination with chemotherapy for the treatment of diffuse Large B-cell Lymphoma
Statement issued by the company (Announcement) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the